Tumor Lysis Syndrome Occurring After the Administration of Rituximab for Posttransplant Lymphoproliferative Disorder

S. A. Francescone; B. Murphy; J. T. Fallon; K. Hammond; S. Pinney

doi:10.1016/j.transproceed.2009.03.060

Tumor Lysis Syndrome Occurring After the Administration of Rituximab for Posttransplant Lymphoproliferative Disorder

S. A. Francescone, B. Murphy, J. T. Fallon, K. Hammond, S. Pinney

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Tumor lysis syndrome (TLS) may occur after the administration of rituximab for lymphoproliferative disorders. We describe the case of a heart transplant recipient who developed TLS after a single dose of rituximab for the treatment of posttransplant lymphoproliferative disorder. Because rituximab is being used more frequently, it is important for transplant physicians to be aware of this potential complication particularly after administering the first dose.

Original language	English
Pages (from-to)	1946-1948
Number of pages	3
Journal	Transplantation Proceedings
Volume	41
Issue number	5
DOIs	https://doi.org/10.1016/j.transproceed.2009.03.060
State	Published - Jun 2009

Access to Document

10.1016/j.transproceed.2009.03.060

Cite this

@article{4a67067f115846948375861b19413688,

title = "Tumor Lysis Syndrome Occurring After the Administration of Rituximab for Posttransplant Lymphoproliferative Disorder",

abstract = "Tumor lysis syndrome (TLS) may occur after the administration of rituximab for lymphoproliferative disorders. We describe the case of a heart transplant recipient who developed TLS after a single dose of rituximab for the treatment of posttransplant lymphoproliferative disorder. Because rituximab is being used more frequently, it is important for transplant physicians to be aware of this potential complication particularly after administering the first dose.",

author = "Francescone, {S. A.} and B. Murphy and Fallon, {J. T.} and K. Hammond and S. Pinney",

year = "2009",

month = jun,

doi = "10.1016/j.transproceed.2009.03.060",

language = "English",

volume = "41",

pages = "1946--1948",

journal = "Transplantation Proceedings",

issn = "0041-1345",

publisher = "Elsevier Inc.",

number = "5",

}

TY - JOUR

T1 - Tumor Lysis Syndrome Occurring After the Administration of Rituximab for Posttransplant Lymphoproliferative Disorder

AU - Francescone, S. A.

AU - Murphy, B.

AU - Fallon, J. T.

AU - Hammond, K.

AU - Pinney, S.

PY - 2009/6

Y1 - 2009/6

N2 - Tumor lysis syndrome (TLS) may occur after the administration of rituximab for lymphoproliferative disorders. We describe the case of a heart transplant recipient who developed TLS after a single dose of rituximab for the treatment of posttransplant lymphoproliferative disorder. Because rituximab is being used more frequently, it is important for transplant physicians to be aware of this potential complication particularly after administering the first dose.

AB - Tumor lysis syndrome (TLS) may occur after the administration of rituximab for lymphoproliferative disorders. We describe the case of a heart transplant recipient who developed TLS after a single dose of rituximab for the treatment of posttransplant lymphoproliferative disorder. Because rituximab is being used more frequently, it is important for transplant physicians to be aware of this potential complication particularly after administering the first dose.

UR - http://www.scopus.com/inward/record.url?scp=67249166261&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2009.03.060

DO - 10.1016/j.transproceed.2009.03.060

M3 - Article

C2 - 19545762

AN - SCOPUS:67249166261

SN - 0041-1345

VL - 41

SP - 1946

EP - 1948

JO - Transplantation Proceedings

JF - Transplantation Proceedings

IS - 5

ER -

Tumor Lysis Syndrome Occurring After the Administration of Rituximab for Posttransplant Lymphoproliferative Disorder

Abstract

Access to Document

Fingerprint

Cite this